Advanced search
Publication Cover
Degenerative Neurological and Neuromuscular Disease Volume 9, 2019 - Issue
Submit an article Journal homepage
202
Views
1
CrossRef citations to date
0
Altmetric
Review

Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Shaila D Ghanekar1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA
,
Wai Wai Miller1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA;3 USF Movement Disorders Neuromodulation Center, Department of Neurology, Tampa, FL, USAORCID Iconhttps://orcid.org/0000-0003-2913-6676
ORCID Icon,
Colin J Meyer4 Reata Pharmaceuticals, Inc., Department of Product Development, Irving, TX, USA
,
Kevin J Fenelon1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA
,
Alvin Lacdao1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA
&
Theresa A Zesiewicz1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA;3 USF Movement Disorders Neuromodulation Center, Department of Neurology, Tampa, FL, USA;5 James A. Haley Veterans’ Hospital, Department of Neurology, Tampa, FL, USACorrespondence[email protected]
Pages 103-107 | Published online: 15 Oct 2019

References

  • Delatycki MB, Williamson R, Forrest SM. Friedreich ataxia: an overview. J Med Genet. 2000;37(1):1–8. doi:10.1136/jmg.37.1.110633128
  • Lupoli F, Vannocci T, Longo G, Niccolai N, Pastore A. The role of oxidative stress in Friedreich’s ataxia. FEBS Lett. 2017;592(5):718–727. doi:10.1002/1873-3468.1292829197070
  • Bidichandani SI, Delatycki MB. Friedreich ataxia. GeneReviews [Internet], University of Washington, Seattle; 1998 [updated 2017].
  • Bürk K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias. 2017;4(1):1–9. doi:10.1186/s40673-017-0062-x28074147
  • La Pean A, Jeffries N, Grow C, Ravina B, Di Prospero NA. Predictors of progression in patients with Friedreich ataxia. Mov Disord. 2008;23(14):2026–2032. doi:10.1002/mds.2224818759347
  • Cook A, Giunti P. Friedreich’s ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124:19–30. doi:10.1093/bmb/ldx03429053830
  • Strawser C, Schadt K, Hauser L, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17(9):895–907. doi:10.1080/14737175.2017.135672128724340
  • Aranca TV, Jones TM, Shaw JD, et al. Emerging therapies in Friedreich’s ataxia. Neurodegener Dis Manag. 2016;6(1):49–65. doi:10.2217/nmt.15.7326782317
  • Lagedrost S, Sutton M, Cohen M, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month Phase III study (IONIA). Am Heart J. 2011;161:639–645.21392622
  • Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart. 2002;87(4):346–349. doi:10.1136/heart.87.4.34611907009
  • Zesiewicz TA, Heerinckx F, De Jager R, et al. Randomized, clinical trial of RT001: early signals of efficacy in Friedreich’s ataxia. Mov Disord. 2018;33:1000–1005. doi:10.1002/mds.2735329624723
  • Orphan products: hope for people with rare diseases. U.S. Food & Drug Administration. Available from: https://www.fda.gov/drugs/resourcesforyou/consumers/ucm143563.htm Accessed 911, 2019.
  • Shan Y, Schoenfeld RA, Hayashi G, et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model. Antioxid Redox Signal. 2013;19(13):1481–1493. doi:10.1089/ars.2012.453723350650
  • Petrillo S, Piermarini E, Pastore A, et al. Nrf2-inducers counteract neurodegeneration in frataxin-silenced motor neurons: disclosing new therapeutic targets for Friedreich’s ataxia. Int J Mol Sci. 2017;18:2173. doi:10.3390/ijms18102173
  • Lynch D, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018;6(1):15–26. doi:10.1002/acn3.66030656180
  • Friedman LS, Farmer JM, Perlman S, et al. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010;25(4):426–432. doi:10.1002/mds.2291220063431
  • RTA 408 Capsules in Patients with Friedreich’s Ataxia. ClinicalTrials.gov. 2014 [ updated 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02255435 Accessed 911, 2019.
  • Felig P. The glucose-alanine cycle. Metabolism. 1973;22(2):179–207. doi:10.1016/0026-0495(73)90269-24567003
  • Osburn WO, Yates MS, Dolan PD, et al. Genetic or pharmacologic amplification of Nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci. 2008;104(1):218–227. doi:10.1093/toxsci/kfn07918417483
  • Zhang YK, Yeager RL, Tanaka Y, Klaassen CD. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicol Appl Pharmacol. 2010;245(3):326–334. doi:10.1016/j.taap.2010.03.01620350562
  • Johnson DA, Johnson JA. Nrf2–a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med. 2015;88(Pt B):253–267. doi:10.1016/j.freeradbiomed.2015.07.14726281945
  • Ramsey CP, Glass CA, Montgomery MB, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol. 2007;66(1):75–85. doi:10.1097/nen.0b013e31802d6da917204939

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.